FindTrial
Sign In

Study on Safety and Cost Calculation of DPP-IV inhibitor Use in Type 2 Diabetic Patients

Drug Safety Profile and Cost Utility Analysis for Optimal DPP-IV Inhibitor Therapy in Type 2 Diabetic Patients

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2022/01/039294
Enrollment
300
Registered
2022-01-10
Start date
Unknown
Completion date
Unknown
Last updated
2022-02-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E118- Type 2 diabetes mellitus with unspecified complications

Interventions

None listed

Sponsors

Dr TMA PAI FELLOWSHIP MAHE MANIPAL
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All type 2 diabetic patients aged between 40- 85 years on antidiabetic agents within the past six months of study initiation.

Exclusion criteria

Exclusion criteria: Type 1 diabetes mellitus, pregnancy, lactation, any malignancies, HIV infection, and patients on immunosuppressants

Design outcomes

Primary

MeasureTime frame
Cost-effectiveness analysis (CEA) and Cost-utility analysis (CUA) in type 2 diabetes patients who are on DPP-IV inhibitorsTimepoint: At baseline and followed every 6 months for 2.5 years with a minimum of 2 follow-up—

Secondary

MeasureTime frame
Diabetic complications such as hypoglycemia, nephropathy, neuropathy, and cardiovascular diseases Adverse drug reactions Number of readmissionsTimepoint: every 6 months followup along with baseline details—

Countries

India

Contacts

Public ContactLEELAVATHI D ACHARYA

MANIPAL COLLEGE OF PHARMACEUTICAL SCIENCES

leela.da@manipal.edu9448159927

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026